# Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

> **NCT02095132** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 76 (actual)

## Conditions studied

- Central Nervous System Embryonal Tumor With Rhabdoid Features
- Central Nervous System Embryonal Tumor, Not Otherwise Specified
- Central Nervous System Ganglioneuroblastoma
- Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
- Pineoblastoma
- Primary Central Nervous System Neoplasm
- Recurrent Childhood Central Nervous System Embryonal Neoplasm
- Recurrent Malignant Solid Neoplasm
- Recurrent Medulloblastoma
- Recurrent Neuroblastoma
- Recurrent Rhabdomyosarcoma
- Refractory Malignant Solid Neoplasm
- Refractory Medulloblastoma
- Refractory Neuroblastoma
- Refractory Rhabdomyosarcoma

## Interventions

- **DRUG:** Adavosertib
- **DRUG:** Irinotecan Hydrochloride

## Key facts

- **NCT ID:** NCT02095132
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-28
- **Primary completion:** 2020-12-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02095132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02095132, "Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02095132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*